Answers are grounded in this paper and cite their sources.
This is the protocol for a review and there is no abstract. The objectives are as follows: To investigate the effects of non-monthly versus monthly intravitreal injection of an anti-VEGF agent on best-corrected visual acuity (BCVA) in people with newly diagnosed nAMD at one-year follow-up.
No takes yet. Share an insight, caveat, or question.
Li et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: